Akèy › Urtikè kronik
Etid klinik pou Urtikè kronik ap rekrite nan Etazini
8 etid pou Urtikè kronik ap rekrite patisipan nan sit atravè Etazini.
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06865651A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06868212An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 16, 2026 · NCT06927999A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT07219615A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Tout sèks · Mizajou May 11, 2026 · NCT07408219A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Apr 21, 2026 · NCT07540910Remibrutinib in Real-world Clinical Practice
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT07358364Remibrutinib in Real-world Clinical Practice - a US Sub-study
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Tout sèks · Mizajou Feb 13, 2026 · NCT07358780Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.